- Kaurenoic acid
-
- $59.00
-
2026-07-15
- CAS:6730-83-2
- Purity: 99.76%
- Supply Ability: 10g
- kaurenoic acid
-
- $8.00
-
2026-07-09
- CAS:6730-83-2
- Min. Order: 1kg
- Purity: 99%
- Kaurenoic acid
-
-
2023-02-24
- CAS:6730-83-2
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | kaurenoic acid Basic information |
| Product Name: | kaurenoic acid | | Synonyms: | kaurenoic acid;(-)-Kaur-16-en-18-oic acid;Cunabic acid;Kaurane-16-ene-18-oic acid;ent-Kaur-16(17)-en-19-oic acid;ent-Kaur-16-en-19-oic acid;NSC 339145;Kaur-16-en-18-oic acid,(4a)- | | CAS: | 6730-83-2 | | MF: | C20H30O2 | | MW: | 302.45 | | EINECS: | | | Product Categories: | | | Mol File: | 6730-83-2.mol |  |
| | kaurenoic acid Chemical Properties |
| Melting point | 171-172 °C | | Boiling point | 426.6±34.0 °C(Predicted) | | density | 1.10±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | DMF: 10 mg/ml; DMSO: 25 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.3 mg/ml; Ethanol: 10 mg/ml | | form | A solid | | pka | 4.70±0.40(Predicted) | | color | White to off-white | | Major Application | metabolomics
vitamins, nutraceuticals, and natural products | | InChI | 1S/C20H30O2/c1-13-11-20-10-7-15-18(2,16(20)6-5-14(13)12-20)8-4-9-19(15,3)17(21)22/h14-16H,1,4-12H2,2-3H3,(H,21,22)/t14-,15+,16+,18-,19-,20-/m1/s1 | | InChIKey | NIKHGUQULKYIGE-OTCXFQBHSA-N | | SMILES | C=C1C[C@@]23CC[C@]4([H])[C@@](C(O)=O)(C)CCC[C@@]4(C)[C@]2([H])CC[C@@H]1C3 |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | kaurenoic acid Usage And Synthesis |
| Description | Kaurenoic acid is a diterpene that has been found in C. langsdorffii and has diverse biological activities, including anticancer, antibacterial, antioxidant, and anti-inflammatory properties. It is cytotoxic to 22Rv1 and LNCaP prostate, HT-29, HCT116, SW480, and SW620 colon, and MCF-7 breast cancer cells with IC50 values ranging from 15.03 to 48.87 μg/ml. Kaurenoic acid is active against S. epidermidis, S. capitis, E. faecalis, and S. haemolyticus in vitro (MICs = 6.25-12.5 μg/ml). Kaurenoic acid (50 and 100 mg/kg) reduces colonic myeloperoxidase (MPO) activity and malondialdehyde (MDA) levels in a rat model of acetic acid-induced colitis, as well as colonic tissue damage, leukocytic infiltration, and submucosal edema when administered at a dose of 100 mg/kg. | | Chemical Properties | White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from plants such as Acanthopanax Cortex (1% content) and Bletilla striata leaves. | | Uses | ent-Kaurenoic Acid can be used in biological study. Kinetic profile of guaco syrup metabolites like coumarin, 7-hydroxycoumarin, o-coumaric acid, kaurenoic acid can be performed for identification of alternative route of coumarin metabolism in human plasma. | | Definition | ChEBI: An ent-kaurane diterpenoid that is ent-kauran-19-oic acid in which a double bond is present at position 16(17); exhibits anticancer and anti-HIV 1 activity. | | in vivo | Kaurenoic acid (1-10 mg/kg, i.g., single dose) reduces peritonitis and pain induced by lipopolysaccharides (HY-D1056) in mice[2].
Kaurenoic acid (as a diterpene compound) is the main active ingredient in the root bark extract of A. senegalensis that exhibits anticonvulsant effects in mice[3]. | Animal Model: | Mice induced by LPS[2] | | Dosage: | 1, 3, 10 mg/kg; single dose | | Administration: | i.g. | | Result: | Inhibited LPS-induced mechanical and thermal hyperalgesia, suppressed MPO activity, regulated the redox state of mouse paws, inhibited the production of pro-inflammatory/pain cytokines (such as TNF-α, IL-1β, and IL-33), and enhanced the production of anti-inflammatory/analgesic cytokine IL-10. |
| | References | [1] L.A.F. PAIVA . Anti-inflammatory effect of kaurenoic acid, a diterpene from Copaifera langsdorffii on acetic acid-induced colitis in rats[J]. Vascular pharmacology, 2002, 39 6: Pages 303-307. DOI: 10.1016/s1537-1891(03)00028-4
[2] GENEIVE E. HENRY . Kaurene diterpenes from Laetia thamnia inhibit the growth of human cancer cells in vitro[J]. Cancer letters, 2006, 244 2: Pages 190-194. DOI: 10.1016/j.canlet.2005.12.022
[3] A. C. F. SOARES. Variability of the antibacterial potential among analogue diterpenes against Gram-positive bacteria: considerations on the structure–activity relationship[J]. Canadian Journal of Chemistry, 2019, 62 1. DOI: 10.1139/cjc-2018-0369 |
| | kaurenoic acid Preparation Products And Raw materials |
|